Novel Vascular Anastomosis Increases Access Sites

A hybrid vascular graft is designed to expand treatment options for optimal outflow by creating new access sites in anatomical locations that would have otherwise been abandoned.

The Gore Hybrid Vascular Graft is indicated for use as a vascular prosthesis for replacement or bypass of diseased vessels impacted by aortic aneurysmal, peripheral, vascular, and end stage renal disease (ESRD). Using the graft, surgeons can maximize the number of access sites available for vascular procedures, as well as preserve the amount of access sites available throughout the patient’s long-term therapy. The device simplifies access to vessels with an optional over the wire deployment method that reduces vessel injury and dissection.


The device is designed to address the most common causes of graft failure, which include intimal hyperplasia, thrombosis, and seroma. The expanded polytetrafluoroethylene (ePTFE) vascular prosthesis has a section reinforced with nitinol; this reinforced section is partially constrained to allow for easy insertion and deployment into vessels that are difficult to reach or in challenging anatomical locations. The combination graft also incorporates the Carmeda BioActive Surface (CBAS) with covalently bonded heparin, resulting in a proven thromboresistant surface. The Gore Hybrid Vascular Graft is a product of Gore Medical Products (Flagstaff, AZ, USA).

“The GORE Hybrid Vascular Graft, for the first time, palpably bridges the gap between traditional vascular and endovascular surgery. It is the first significant innovation in vascular grafts in years, providing tremendous versatility,” said Jean Bismuth, MD, an assistant professor at the Methodist DeBakey Heart and Vascular Center (Houston, TX, USA). “The GORE Hybrid Vascular Graft allows the surgeon to create a sutureless anastomosis and displays significant potential for improving hemodynamics.”

Related Links:
Gore Medical Products
Methodist DeBakey Heart and Vascular Center